While vitiligo is an incurable condition, it is manageable through various treatment options. These include FDA-approved and off-label medications, light therapy, microsurgery, and adjunctive therapies. The effectiveness of these treatments varies based on factors such as the patient's age, time since disease onset, skin phototype, genetic background, and other considerations.

Leading the drug treatments are advanced JAK inhibitors like Opzelura® from biotech firm Incyte, and Litfulo® from pharmaceutical giant Pfizer, in the last phase of clinical trials. These drugs act as immune system regulators, targeting specific communication pathways to control irregular immune responses.

Opzelura® (1.5% ruxolitinib), notably the first FDA-approved drug for vitiligo, is a topical treatment suitable for individuals aged 12 and above. Recommended usage involves twice-daily application to affected areas, especially on the face, with no fixed limit on duration of use, provided there are visible improvements. Results vary; some may see benefits within 24 weeks, while others might need up to a year. Dermatologists often prioritize its use on the face and sensitive areas like the genitals, areola, or ventral breast. Research suggests that low-level light exposure may enhance the drug's effectiveness, although the drug alone can maintain repigmentation.

The drug development pipeline for vitiligo treatments is promising. Currently, a dozen pharmaceutical and biotech companies are actively investing in vitiligo research and development programs. This ongoing research holds the potential for new and more effective treatments in the future.